Novo Trades at Hefty Discount to Lilly Even After 350% Rally
- Wegovy maker still cheaper compared to US competitor
- Shares have surged since 2020 on weight-loss drug demand
This article is for subscribers only.
Novo Nordisk A/S’s more than 350% rally over the past four years may have further to run if the weight-loss drug firm is to close the gap with its US competitor.
While analysts have cautioned that the stock’s valuation is getting ahead of itself, its 30% discount to Eli Lilly & Co. suggests otherwise.